Results 131 to 140 of about 8,958 (210)

Oncolytic Virotherapy for Solid Tumors

Oncolytic viruses (OVs) are naturally occurring or genetically engineered viruses that selectively replicate in and destroy tumor cells while sparing normal tissues.
Asawa, Palash, Zheng, Xena, Merchan, Jaime Rafael   +2 more
core   +1 more source

Redemption for the Field of Oncolytic Virotherapy

Molecular Therapy, 2011
The field of targeted and transgene-armed oncolytic viruses has been through a cycle of boom (mid-1990s) and bust (the early 2000s). In January 2011, however, Amgen—the biggest independent biotechnology company in the world—jumped headfirst into the field by acquiring Biovex for $425 million and promising potential success-based milestone payments of ...
openaire   +2 more sources

Enhancing the therapeutic potential of oncolytic virotherapy for melanoma treatment

reservedMelanoma remains a globally relevant malignancy. Although various treatments have been developed over time, few are effective against rarer mutations.
PAROLIN, BEATRICE
core  

Macrophage delivered oncolytic virotherapy in triple negative breast cancer [PDF]

Background: Triple negative breast cancer (TNBC) is a high cause of morbidity and mortality. Novel treatments for TNBC are needed to extend the overall survival of patients with metastatic TNBC where the prognosis remains poor.
Kwan, Amy
core  

Immune mediated and direct killing of colorectal cancer by reovirus [PDF]

, 2012
Colorectal cancer remains the second most prevalent cancer in the world. Novel treatment strategies are necessary, especially for the treatment of metastatic disease.
Adair, Robert Allan
core  

Oncolytic virotherapy [PDF]

, 2014
Usprkos brojnim dosad razvijenim terapijama, rak je jedan od najčešćih uzročnika smrti današnjice te njegovo liječenje predstavlja pravi izazov. U posljednje se vrijeme intenzivno radi na razvijanju onkolitičke viroterapije, koja se ističe svojom ...
Kavšek, Alan
core  

Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

Correction to: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 ...
Colman, Howard, Boutros, Paul, Gomez-Manzano, Candelaria, Rodriguez, Analiz, Puduvalli, Vinay K., Aldape, Kenneth, Nassiri, Farshad, Yankelevich, Maxim, Patil, Vikas, Peereboom, David M., Mason, Warren P., Alonso, Marta M., Robbins, Joan, Sonabend, Adam M., Nair, Suresh G., Melear, Jason M., Yamaguchi, Takafumi N., Daras, Mariza, Chen, Clark C., Khagi, Simon, Zadeh, Gelareh, Groves, Morris D., Gao, Andrew, Liu, Jeff, Dang, Rachel M. A., Kumthekar, Priya U., López-Janeiro, Álvaro, Singh, Olivia, Stupp, Roger, Ramakrishna, Rohan, Aiken, Robert, Fueyo, Juan, Yefet, Leeor S., de Andrea, Carlos E., Vogelbaum, Michael A., Ong, Shirley S., Kaley, Thomas, Cloughesy, Timothy F., Lang, Frederick F.   +38 more
core   +1 more source

Fire in an Icy Desert: Oncolytic Virotherapy for Pancreatic Adenocarcinoma. [PDF]

Pharmaceutics
Rossetto A, Reale A.
europepmc   +1 more source

Oncolytic Virotherapy in Solid Tumors: A Current Review. [PDF]

BioDrugs
Chen C, Cillis J, Deshpande S, Park AK, Valencia H, Kim SI, Lu J, Vashi Y, Yang A, Zhang Z, Woo Y, Fong Y, Chaurasiya S.   +12 more
europepmc   +1 more source

Intrinsic immune properties of carrier MSC impact on the clinical outcome of children with solid tumors receiving oncolytic virotherapy. [PDF]

Exp Hematol Oncol
Morales-Molina A, Franco-Luzón L, Garcia-Rodriguez P, González-Murillo A, García-Castro J, Ramírez M.   +5 more
europepmc   +1 more source